GlassScriptPhysician profile
Carlos S Clark
NPI 1063851277
$4,106.90
in general payments reported to CMS, 2019-2025
36 companies · $510 in 2025
The $510 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $489 · 2021: $980 · 2022: $988 · 2023: $291 · 2024: $462 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $578.53 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $470.51 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $418.04 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $316.28 | 2021-2024 | Ozempic |
| Abbvie INC. | $289.77 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $205.82 | 2020-2024 | Trintellix |
| Nevro Corp. | $197.27 | 2021-2023 | Senza |
| Astellas Pharma US INC | $184.33 | 2019-2024 | Veozah |
| Amgen INC. | $144.25 | 2019-2025 | Evenity, Repatha, Repatha |
| Biohaven Pharmaceuticals, INC. | $138.33 | 2021 | |
| Amarin Pharma, INC. | $124.04 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $115.22 | 2019-2022 | |
| Abbott Laboratories | $109.52 | 2021-2023 | Freestyle Libre 3 |
| Allergan, INC. | $75.86 | 2019-2020 | |
| Pfizer INC. | $73.35 | 2019-2025 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.